Medical technology company Tasso announced today it has gained an additional $2.9 million in Phase II SBIR grant funding to advance its HemoLink­ technology.

According to a release, Tasso, along with development partner GenTegra, are developing an integrated device that is able to collect blood from patients and stabilize biomarkers at ambient temperatures without requiring cold chain transportation.

“Together, (Tasso and GenTegra) will modernize the diagnostic process by providing superior and affordable ‘in home’ and ‘point-of-care’ access to healthcare,” Tasso CEO Ben Moga said in a statement.

Tasso previously secured $2.3 million in a Phase I SBIR grant in February 2014.